Argenx stock holds focus on Vyvgart growth and 2025 revenue

Argenx (NL0010832176) remains a closely watched name because its latest reported revenue, profit path and product roll-out still define the stock narrative. The company reported 2025 revenue of EUR 2.19 billion, up from EUR 1.31 billion in 2024, while diluted earnings per share improved to EUR 7.04 from EUR 0.87 in the prior year.

Revenue rose 67%

In 2025, Argenx reported total revenue of EUR 2.19 billion versus EUR 1.31 billion in 2024, a year-on-year increase of about 67%. The same set of results showed diluted EPS of EUR 7.04, compared with EUR 0.87 a year earlier, which gives investors a clearer read-through on operating leverage.

Gross margin also stayed high at 92% in 2025, underlining the profitability profile of the antibody platform. That matters because a company with a narrow product base can see the earnings line move faster than the top line when uptake accelerates.

Profitability improved in 2025

Net income reached EUR 578 million in 2025, up from EUR 69 million in 2024, showing a much stronger bottom-line contribution. Operating income also increased to EUR 579 million from EUR 91 million in the prior year, which supports the view that the business scaled through the period rather than relying on one-off items.

Vyvgart remains the core commercial driver, and the company’s 2025 figures show why the market keeps treating the franchise as more than a single-quarter story. With revenue, EPS and operating income all advancing in the same year, the main question for investors is whether that pace can hold through the next reporting cycle.

Vyvgart still drives the story

Vyvgart is Argenx’s lead product and the central reason the company continues to attract attention from biotech investors. The product line sits at the center of the commercial model, so any shift in uptake or geographic expansion has an outsized effect on group revenue and earnings.

That makes the 2025 growth profile particularly important. Revenue of EUR 2.19 billion, net income of EUR 578 million and gross margin of 92% together point to a business that entered 2026 with visible operating momentum.

Shares near the latest reference point

A dated market price was not available in the supplied search results, so the stock discussion is best anchored in the latest reported fundamentals. For Argenx, the 2025 figures provide the clearest reference point for current valuation work.

Argenx stock on Nasdaq remains tied to the company’s ability to extend Vyvgart-led growth into 2026 while keeping the margin profile near the 2025 level. The latest reported numbers leave a straightforward baseline: EUR 2.19 billion in revenue, EUR 578 million in net income and EUR 7.04 in diluted EPS for 2025.